Sylvant (siltuximab) is an antibody pharmaceutical. Siltuximab was first approved as Sylvant on 2014-04-23. It is used to treat castleman disease in the USA. It has been approved in Europe to treat focal nodular hyperplasia. The pharmaceutical is active against interleukin-6.
|Indication||castleman disease, focal nodular hyperplasia|
|Drug Class||Monoclonal antibodies: chimeric, tumors as target|